Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma.

Area of Science:

• Oncology
• Medical Research

Background:

• Advanced renal cell carcinoma (RCC) treatment typically targets angiogenesis via tyrosine kinase inhibitors (TKIs) and immune checkpoints like PD-1/PD-L1 and CTLA4.
• Current first-line strategies often combine these approaches.
• Optimal sequencing of therapies after resistance develops in later treatment lines remains less understood.

Purpose of the Study:

• To review therapeutic options for patients with progressive RCC.
• To address the knowledge gap regarding second- and later-line treatments following resistance to initial therapies.
• To discuss management strategies after double immune checkpoint inhibitors (ICIs) or ICI-TKI combinations.

Main Methods:

• Literature review of current therapeutic options.
• Analysis of treatment strategies for advanced RCC.
• Discussion of clinical data for progressive disease management.

Main Results:

• Identifies available treatment modalities for advanced RCC post-resistance.
• Highlights the challenges in selecting subsequent therapies.
• Summarizes the landscape of options after dual ICI or ICI-TKI failure.

Conclusions:

• Further research is needed to establish optimal treatment algorithms for advanced RCC.
• Understanding treatment sequencing is crucial for improving outcomes in resistant cases.
• This review provides insights into managing progressive RCC after standard first-line therapies.